cjm112
mAbexperimental
Clinical trial activity
6 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2013 (NCT01828086)
Timeline
Indications
Mechanism of action
- Interleukin 17AINHIBITOR
IL17A inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- cjm112
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03299686 | Phase 2 | Nov 6, 2017 | Novartis |
| NCT03111992 | Phase 1 | May 25, 2017 | Novartis |
| NCT02998671 | Phase 2 | Dec 22, 2016 | Novartis |
| NCT02900664 | Phase 1 | Aug 23, 2016 | Novartis |
| NCT02421172 | Phase 2 | Apr 13, 2015 | Dermatologisk Afdeling, Roskilde, Denmark, Dermato-verenologisk afdeling S, Denmark, Dessau Medical Center, Erasmus University Rotterdam, Novartis, Ruhr University Bochum, University of Amsterdam, University of Bern, University of Groningen, University of Zurich |
| NCT01828086 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2013 | Novartis |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 6 | 6 | 2 | 2013 |
| Dermatologisk Afdeling, Roskilde, Denmark | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Dermato-verenologisk afdeling S, Denmark | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Dessau Medical Center | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Ruhr University Bochum | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Bern | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Groningen | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Zurich | Academic/Hospital | 1 | 0 | 1 | 2015 |
10 organizations
Page 1 / 1